Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix cuts jobs as FDA request for more Vasovist data means a year's delay

This article was originally published in Clinica

Executive Summary

The US approval of Epix Pharmaceuticals' blood-pool contrast agent, Vasovist, could be delayed by a further year after the FDA issued the firm with another "approvable" letter requesting more data. Following the announcement, Epix said it would be making "substantial" cuts to its workforce and research plans in a bid to refocus its resources.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT058077

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel